Clinical Depth That Changes Outcomes Dr
The peptide calculator helps translate between units and volume for any concentration
Upfront: $4.9 billion to acquire all shares Potential Total Value: Up to $7.3 billion if all milestones are met Premium: ~40% premium over Metsera's recent share price This marks Pfizer's major strategic pivot to re-enter the high-stakes obesity market via acquisition
Wegovy is a GLP-1 receptor agonist administered weekly by subcutaneous injection for chronic weight management in adults with obesity or overweight with comorbidities
Some patients taking Wegovy may experience: Nausea or vomiting during bowel preparation Difficulty tolerating the full volume of preparation solution Variable bowel cleansing effectiveness To optimise bowel preparation, follow your endoscopy unit's specific instructions, which typically include: Split-dose regimens (taking part of the preparation the evening before and the remainder on the morning of the procedure) Clear guidance on when to stop eating solid foods (usually 24 hours before) Instructions on when you can last drink clear fluids (typically up to 2 hours before the procedure) Patient strategies to improve tolerance include: Taking the preparation solution slowly, sipping rather than gulping Keeping the solution chilled to improve palatability Using flavour packets if provided Remaining mobile during preparation to aid bowel transit Staying well-hydrated with permitted clear fluids If you experience severe vomiting, inability to complete the preparation, or signs of dehydration (dizziness, reduced urination, extreme thirst), contact your endoscopy unit or seek medical advice promptly
